Evidence map›Paper›PMID 39703195›Full record

ReviewDrug design, development and therapy2024

Pharmacological Mechanisms of Cryptotanshinone: Recent Advances in Cardiovascular, Cancer, and Neurological Disease Applications.

Ziyao Zheng, Liyuan Ke, Shumin Ye, Peiying Shi, Hong Yao

Abstract readReview
In one paragraph

Review in Drug design, development and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. International journal of molecular sciences · 2025
    Pooled it
  2. Article
  3. Review
  4. Danshen (Antioxidants (Basel, Switzerland) · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ziyao ZhengDepartment of Pharmaceutical Analysis, School of Pharmacy, Fujian Medical University, Fuzhou, 350122, People's Republic of China.ORCID 0009-0008-3042-2331
Liyuan KeDepartment of Pharmaceutical Analysis, School of Pharmacy, Fujian Medical University, Fuzhou, 350122, People's Republic of China.
Shumin YeDepartment of Pharmaceutical Analysis, School of Pharmacy, Fujian Medical University, Fuzhou, 350122, People's Republic of China.
Peiying ShiDepartment of Traditional Chinese Medicine Resource and Bee Products, College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou, 350002, People's Republic of China.ORCID 0000-0003-1444-3980
Hong YaoDepartment of Pharmaceutical Analysis, School of Pharmacy, Fujian Medical University, Fuzhou, 350122, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cryptotanshinone (CTS) is an important active ingredient of

Indexed as

Cardiovascular DiseasesNeoplasmsNervous System DiseasesPhenanthrenesAnimalsHumanscryptotanshinonePhenanthrenesbioinformatics analysiscryptotanshinonemolecular mechanismpharmacological effects

Identifiers

PMID39703195
PMCPMC11658958

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.